Skip to Content

Negative Selection at Scale: Driving the Next Era of CAR T Immunotherapy Manufacturing

Published on Jan 10, 2025

Rising cancer rates have been featured heavily in the news this year, especially among younger adults. As cancer rates continue to climb, the need for innovative treatments has never been more pressing. Over recent years, immunotherapy, particularly CAR T cell therapy, emerged as a promising approach, offering renewed hope to patients facing challenging diagnoses through a personalized approach. 

However, the increasing demand for these therapies revealed significant bottlenecks in the scalability and efficiency of donor-based T cell isolation methods or allogeneic therapy—a critical step in the CAR T cell therapy process. Akadeum Life Sciences addressed these challenges head-on with the launch of the Alerion™ Microbubble Cell Separation System, setting a new standard for scalable and gentle cell isolation.

The Growing Demand for Scalable T Cell Isolation

CAR T cell therapy transforms cancer treatment by harnessing the power of a patient’s immune system. This therapy involves isolating T cells, engineering them to target cancer cells, and reintroducing them into the patient. Recent FDA approvals and promising clinical trial results have driven unprecedented growth in CAR T therapies, but this surge has also underscored the need for more scalable and efficient solutions.

Challenges in Current Methods

Traditional T cell isolation methods often struggle to meet the demands of large-scale applications. Magnetic bead-based systems, while effective, can be expensive, time-consuming, and less compatible with high-throughput workflows. These limitations become even more pronounced in allogeneic therapies, which require isolating high-quality T cells from donor-derived samples for use in multiple patients.

Allogeneic Therapies: The Future of CAR T

Unlike autologous therapies, where cells are sourced from the patient, allogeneic CAR T therapies rely on donor cells to create “off-the-shelf” treatments. These therapies promise greater accessibility and affordability, but they also demand more stringent quality control and scalability in T cell isolation, given the increased possibility of host rejection. 

Negative selection—the process of removing unwanted cells while preserving the target population—is particularly crucial in ensuring high purity in untouched T cells for allogeneic workflows.

Akadeum’s Alerion™ Microbubble Cell Separation System

Akadeum Life Sciences has revolutionized cell isolation with its Alerion™ Microbubble Cell Separation System, offering a scalable and efficient alternative to traditional methods. The Alerion™ system gently isolates cells by utilizing buoyant microbubbles, minimizing stress and maximizing viability.

Advantages of Microbubble-Based Negative Selection

  • Scalability: The Alerion™ system can scale from process development needs to large-scale manufacturing.
  • Cell health: Microbubble-based isolation’s gentle nature ensures higher cell viability than magnetic bead methods, preserving the functional integrity of T cells.
  • Workflow integration: The Alerion™ system’s compatibility with existing processes enables researchers to enhance their workflows without significant operational changes.

These features make the Alerion™ system ideal for advancing CAR T cancer treatment and allogeneic therapies.

Meeting the Needs of Allogeneic Therapies With Negative Selection

Negative selection is well suited for allogeneic workflows by removing unwanted cell types while preserving the integrity of the desired T cell population. The Alerion™ system excels in this area – plus offers unparalleled precision and scalability. By maintaining cell health and purity, Akadeum’s technology meets the rigorous demands of allogeneic manufacturing, paving the way for broader clinical applications.

Proven Solutions: Akadeum T Cell Isolation Kits

Akadeum’s suite of T cell isolation kits is tailored to meet the diverse needs of researchers and clinicians:

  • Human T Cell Depletion Kit: Precisely removes unedited T cells, ensuring more cells of interest for downstream formulation. Available in Clinical Ready, GMP, and RUO grade formats.
  • Human T Cell Leukopak Isolation Kit: Optimized for high-throughput isolation from donor-derived leukopaks, ideal for large-scale manufacturing. Available in GMP and RUO grade formats. 

Combined with the Alerion™ Microbubble Cell Separation System, these kits provide researchers with process efficiency and healthy cells needed to achieve consistent, scalable results in CAR T cancer treatment development and manufacturing.

The Future of CAR T Therapeutic Manufacturing With Akadeum

The demand for scalable and efficient solutions will only grow as immunotherapy evolves. Akadeum Life Sciences is at the forefront of this revolution, empowering researchers and clinicians with cutting-edge cell isolation technologies that enhance the manufacturing of CAR T therapies.

By addressing the unique challenges of allogeneic therapy and offering innovative solutions like the Alerion™ Microbubble Cell Separation System, Akadeum is shaping the future of cancer treatment manufacturing.

Learn More

Explore how Akadeum’s Alerion™ Microbubble Cell Separation System and T Cell Isolation Kits can elevate your CAR T cancer treatment manufacturing workflows. Contact our team of experts to learn more about our scalable immunotherapy and allogeneic solutions.

 

 

Back to Top